Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

A Survey of Academic Intensivists' Use of Neuromuscular Blockade in Subjects With ARDS.

Dodia NN, Richert ME, Deitchman AR, Quinn CC, Marciniak ET, Brown CH, Terrin ML, Amariei DE, Shanholtz CB, Hasday JD.

Respir Care. 2019 Sep 10. pii: respcare.07026. doi: 10.4187/respcare.07026. [Epub ahead of print]

PMID:
31506341
2.

An mHealth Diabetes Intervention for Glucose Control: Health Care Utilization Analysis.

Quinn CC, Swasey KK, Torain JM, Shardell MD, Terrin ML, Barr EA, Gruber-Baldini AL.

JMIR Mhealth Uhealth. 2018 Oct 15;6(10):e10776. doi: 10.2196/10776.

3.

A multimodal rehabilitation program for patients with ICU acquired weakness improves ventilator weaning and discharge home.

Verceles AC, Wells CL, Sorkin JD, Terrin ML, Beans J, Jenkins T, Goldberg AP.

J Crit Care. 2018 Oct;47:204-210. doi: 10.1016/j.jcrc.2018.07.006. Epub 2018 Jul 11.

4.

The Impact of a Mobile Diabetes Health Intervention on Diabetes Distress and Depression Among Adults: Secondary Analysis of a Cluster Randomized Controlled Trial.

Quinn CC, Swasey KK, Crabbe JCF, Shardell MD, Terrin ML, Barr EA, Gruber-Baldini AL.

JMIR Mhealth Uhealth. 2017 Dec 7;5(12):e183. doi: 10.2196/mhealth.8910.

5.

Pilot Feasibility Study of Therapeutic Hypothermia for Moderate to Severe Acute Respiratory Distress Syndrome.

Slack DF, Corwin DS, Shah NG, Shanholtz CB, Verceles AC, Netzer G, Jones KM, Brown CH, Terrin ML, Hasday JD.

Crit Care Med. 2017 Jul;45(7):1152-1159. doi: 10.1097/CCM.0000000000002338.

6.

Non-invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA(3)CT): Design of a Phase IIb, placebo-controlled, double-blind, randomized clinical trial of doxycycline for the reduction of growth of small abdominal aortic aneurysm.

Baxter BT, Matsumura J, Curci J, McBride R, Blackwelder WC, Liu X, Larson L, Terrin ML; N-TA(3)CT Investigators.

Contemp Clin Trials. 2016 May;48:91-8. doi: 10.1016/j.cct.2016.03.008. Epub 2016 Mar 25.

7.

Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Merchan LM, Hassan HE, Terrin ML, Waites KB, Kaufman DA, Ambalavanan N, Donohue P, Dulkerian SJ, Schelonka R, Magder LS, Shukla S, Eddington ND, Viscardi RM.

Antimicrob Agents Chemother. 2015 Jan;59(1):570-8. doi: 10.1128/AAC.03951-14. Epub 2014 Nov 10.

8.

Mobile Diabetes Intervention for Glycemic Control in 45- to 64-Year-Old Persons With Type 2 Diabetes.

Quinn CC, Shardell MD, Terrin ML, Barr EA, Park D, Shaikh F, Guralnik JM, Gruber-Baldini AL.

J Appl Gerontol. 2016 Feb;35(2):227-43. doi: 10.1177/0733464814542611. Epub 2014 Aug 6.

PMID:
25098253
9.

Mobile Diabetes Intervention for Glycemic Control: Impact on Physician Prescribing.

Quinn CC, Sareh PL, Shardell ML, Terrin ML, Barr EA, Gruber-Baldini AL.

J Diabetes Sci Technol. 2014 Mar;8(2):362-370. Epub 2014 Feb 5.

10.

Blood alcohol content, injury severity, and adult respiratory distress syndrome.

Afshar M, Smith GS, Terrin ML, Barrett M, Lissauer ME, Mansoor S, Jeudy J, Netzer G.

J Trauma Acute Care Surg. 2014 Jun;76(6):1447-55. doi: 10.1097/TA.0000000000000238.

11.

Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.

Viscardi RM, Othman AA, Hassan HE, Eddington ND, Abebe E, Terrin ML, Kaufman DA, Waites KB.

Antimicrob Agents Chemother. 2013 May;57(5):2127-33. doi: 10.1128/AAC.02183-12. Epub 2013 Feb 25.

12.

Ambient light levels and critical care outcomes.

Verceles AC, Liu X, Terrin ML, Scharf SM, Shanholtz C, Harris A, Ayanleye B, Parker A, Netzer G.

J Crit Care. 2013 Feb;28(1):110.e1-8. doi: 10.1016/j.jcrc.2012.04.012. Epub 2012 Jul 2.

PMID:
22762935
13.

Liberal or restrictive transfusion in high-risk patients after hip surgery.

Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, Magaziner J; FOCUS Investigators.

N Engl J Med. 2011 Dec 29;365(26):2453-62. doi: 10.1056/NEJMoa1012452. Epub 2011 Dec 14.

14.

Cluster-randomized trial of a mobile phone personalized behavioral intervention for blood glucose control.

Quinn CC, Shardell MD, Terrin ML, Barr EA, Ballew SH, Gruber-Baldini AL.

Diabetes Care. 2011 Sep;34(9):1934-42. doi: 10.2337/dc11-0366. Epub 2011 Jul 25. Erratum in: Diabetes Care. 2013 Nov;36(11):3850.

15.

Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Hassan HE, Othman AA, Eddington ND, Duffy L, Xiao L, Waites KB, Kaufman DA, Fairchild KD, Terrin ML, Viscardi RM.

J Clin Pharmacol. 2011 Sep;51(9):1264-75. doi: 10.1177/0091270010382021. Epub 2010 Nov 23.

16.

Transfusion practice in the intensive care unit: a 10-year analysis.

Netzer G, Liu X, Harris AD, Edelman BB, Hess JR, Shanholtz C, Murphy DJ, Terrin ML.

Transfusion. 2010 Oct;50(10):2125-34. doi: 10.1111/j.1537-2995.2010.02721.x.

17.

Sensible approaches for reducing clinical trial costs.

Eisenstein EL, Collins R, Cracknell BS, Podesta O, Reid ED, Sandercock P, Shakhov Y, Terrin ML, Sellers MA, Califf RM, Granger CB, Diaz R.

Clin Trials. 2008;5(1):75-84. doi: 10.1177/1740774507087551.

PMID:
18283084
18.

Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS).

Carson JL, Terrin ML, Magaziner J, Chaitman BR, Apple FS, Heck DA, Sanders D; FOCUS Investigators.

Transfusion. 2006 Dec;46(12):2192-206. Review. No abstract available.

PMID:
17176334
19.

Coronary artery bypass graft surgery and cognitive performance.

Dupuis G, Kennedy E, Lindquist R, Barton FB, Terrin ML, Hoogwerf BJ, Czajkowski SM, Herd JA; Post CABG Biobehavioral Study Investigators.

Am J Crit Care. 2006 Sep;15(5):471-8; quiz 479.

20.

L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial.

Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G.

JAMA. 2006 Jan 4;295(1):58-64.

PMID:
16391217
21.

Evaluating and implementing data and safety monitoring plans.

Terrin ML.

J Investig Med. 2004 Nov;52(7):459-63. doi: 10.1136/jim-52-07-38.

PMID:
15651262
22.

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

Canner PL, Furberg CD, Terrin ML, McGovern ME.

Am J Cardiol. 2005 Jan 15;95(2):254-7.

PMID:
15642562
23.

A case control etiologic study of sarcoidosis: environmental and occupational risk factors.

Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, Terrin ML, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Thompson BW, Teirstein AS, Yeager H Jr, Johns CJ, Rabin DL, Rybicki BA, Cherniack R; ACCESS Research Group.

Am J Respir Crit Care Med. 2004 Dec 15;170(12):1324-30. Epub 2004 Sep 3.

PMID:
15347561
24.

Quality of life after coronary artery bypass graft: results from the POST CABG Trial.

Fox NL, Hoogwerf BJ, Czajkowski S, Lindquist R, Dupuis G, Herd JA, Campeau L, Hickey A, Barton FB, Terrin ML; POST CABG Study Investigators.

Chest. 2004 Aug;126(2):487-95.

PMID:
15302735
25.

Comparison of health-related quality-of-life outcomes of men and women after coronary artery bypass surgery through 1 year: findings from the POST CABG Biobehavioral Study.

Lindquist R, Dupuis G, Terrin ML, Hoogwerf B, Czajkowski S, Herd JA, Barton FB, Tracy MF, Hunninghake DB, Treat-Jacobson D, Shumaker S, Zyzanski S, Goldenberg I, Knatterud GL; POST CABG Biobehavioral Study Investigators.

Am Heart J. 2003 Dec;146(6):1038-44.

PMID:
14660996
26.

Anemia and postoperative rehabilitation.

Carson JL, Terrin ML, Jay M.

Can J Anaesth. 2003 Jun-Jul;50(6 Suppl):S60-4. Review.

PMID:
14629055
27.

Two year prognosis of sarcoidosis: the ACCESS experience.

Judson MA, Baughman RP, Thompson BW, Teirstein AS, Terrin ML, Rossman MD, Yeager H Jr, McLennan G, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki BA, Weinberger SE, Knatterud GL, Cherniak R; ACCESS Research Group.

Sarcoidosis Vasc Diffuse Lung Dis. 2003 Oct;20(3):204-11.

PMID:
14620163
29.

Angiographic changes in saphenous vein grafts are predictors of clinical outcomes.

Knatterud GL, White C, Geller NL, Campeau L, Forman SA, Domanski M, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Terrin ML, Rosenberg Y.

Am Heart J. 2003 Feb;145(2):262-9.

PMID:
12595843
30.

Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial.

Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin ML, Williams DO, Forman SA; Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT).

JAMA. 2002 Apr 17;287(15):1943-51. Erratum in: JAMA 2002 Jun 26;287(24):3212.

PMID:
11960536
31.

Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS).

Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, Terrin ML, Moller DR, Barnard J, Baughman RP, DePalo L, Hunninghake G, Johns C, Judson MA, Knatterud GL, McLennan G, Newman LS, Rabin DL, Rose C, Teirstein AS, Weinberger SE, Yeager H, Cherniack R; ACCESS Research Group.

Am J Respir Crit Care Med. 2001 Dec 1;164(11):2085-91.

PMID:
11739139
32.

Clinical characteristics of patients in a case control study of sarcoidosis.

Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniak R; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group.

Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1885-9.

PMID:
11734441
33.

Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.

White CW, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, Geller NL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Rosenberg Y, Terrin ML; Post Coronary Artery Bypass Graft Trial Investigators.

Circulation. 2001 Nov 27;104(22):2660-5.

PMID:
11723015
34.

The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.

Walenga JM, Hoppensteadt D, Pifarré R, Fox NL, Forman S, Hunninghake DB, Campeau L, Herd JA, Hoogwerf BJ, Hickey A, Probstfield JL, Terrin ML.

J Thromb Thrombolysis. 2001 Apr;11(2):143-9.

PMID:
11406729
35.

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.

Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C.

Circulation. 2000 Jul 11;102(2):157-65.

PMID:
10889125
36.
37.

Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators.

Walenga JM, Hoppensteadt D, Pifarré R, Cressman MD, Hunninghake DB, Fox NL, Terrin ML, Probstfield JL.

J Thromb Thrombolysis. 1999 Jun;7(3):313-8.

PMID:
10373714
38.

Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis.

Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr.

Sarcoidosis Vasc Diffuse Lung Dis. 1999 Mar;16(1):75-86. Review.

PMID:
10207945
39.

A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture.

Carson JL, Terrin ML, Barton FB, Aaron R, Greenburg AG, Heck DA, Magaziner J, Merlino FE, Bunce G, McClelland B, Duff A, Noveck H.

Transfusion. 1998 Jun;38(6):522-9.

PMID:
9661685
40.

Individual subject random assignment is the preferred means of evaluating behavioral lifestyle modification.

Terrin ML.

Control Clin Trials. 1997 Dec;18(6):500-5; discussion 514-6. Review.

PMID:
9408713
41.

An extension of stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH).

McMahon RP, Waclawiw MA, Geller NL, Barton FB, Terrin ML, Bonds DR.

Control Clin Trials. 1997 Oct;18(5):420-30.

PMID:
9315425
42.

Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II pilot and randomized clinical trial combined experience.

Sloan MA, Price TR, Terrin ML, Forman S, Gore JM, Chaitman BR, Hodges M, Mueller H, Rogers WJ, Knatterud GL, Braunwald E.

Stroke. 1997 Jun;28(6):1107-14.

PMID:
9183334
43.
44.

Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.

Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ.

Blood. 1997 Feb 1;89(3):1078-88.

45.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

46.

Pulmonary embolism and mortality in patients with COPD.

Carson JL, Terrin ML, Duff A, Kelley MA.

Chest. 1996 Nov;110(5):1212-9.

PMID:
8915223
47.

Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea.

Charache S, Terrin ML, Moore RD, Dover GJ, McMahon RP, Barton FB, Waclawiw M, Eckert SV.

Control Clin Trials. 1995 Dec;16(6):432-46.

PMID:
8925656
49.

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR.

N Engl J Med. 1995 May 18;332(20):1317-22.

50.

Supplemental Content

Loading ...
Support Center